Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00819520 | Ivermectin in the Treatment of Head Lice | PHASE3 | COMPLETED | 812 | — | — | Feb 1, 2004 | Oct 1, 2004 | Aug 22, 2011 | 4 | France, Ireland +2 |
| Arm | Type | Description |
|---|---|---|
| Ivermectin | EXPERIMENTAL | ivermectin Stromectol®) |
| Malathion | ACTIVE_COMPARATOR | malathion(Prioderm®) |
| Name | Type | Description |
|---|---|---|
| ivermectin | DRUG | Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion |
| malathion | DRUG | Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets |
Inclusion Criteria: * Head lice infestation confirmed by detection combing by study staff * previous (within 6 weeks) use of a topical insecticide product * minimum 15kg weight * providing informed consent Exclusion Criteria: * pregnant or nursing patients * households with 7 or more infested pat...